Attention to the proper technique of subcutaneous injection of heparin is important to avoid development of a cJinicaUy significant intramuscular hematoma. In his letter, Thomas gives some suggestions for the administration of subcutaneous heparin that are reasonable and may help avert such complications.Morrison raises concerns about the use of the thigh as a site for subcutaneous injection of heparin. He cites anatomic reasons that might make injection in the thigh more hazardous than injection in the abdomen.1 It is unclear, however, to what extent the observations and case reports that he cites can be generalized to patients receiving low-dose prophylactic heparin. In cited series,1 heparin was administered therapeutically and doses ranged from 50 to 75 mm every 6 hours (5000 to 7500 U every 6 hours), which are higher than prophylactic doses and likely result in therapeutic anticoagulation. Systemic anticoagulation can cause development of both retroperitoneal
Tsapatsaris NP. Site for Subcutaneous Heparin Injection-Reply. Arch Intern Med. 1992;152(1):202–204. doi:10.1001/archinte.1992.00400130192028
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: